Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
YieldMax AMD Option Income Strategy ETF vs Becton Dickinson and Co — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $54.3, while Becton Dickinson and Co trades at $151.94 (market cap $41.87B). The key difference: Becton Dickinson and Co pays a 2.76% dividend while YieldMax AMD Option Income Strategy ETF pays none, and YieldMax AMD Option Income Strategy ETF is trading nearer its 52-week high, Becton Dickinson and Co nearer its low. Which is the better fit depends on your goals.
| AMDY | BDX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $185.39 |
52-Week Low | $29.80 | $135.49 |
Market Cap | — | $41.87B |
Enterprise Value | — | $58.33B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $55.56, up 2.04% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong weekly dividend distributions but lacks traditional valuation metrics. Recent news highlights its high-yield strategy and associated risks of NAV erosion, with support at $54 and resistance at $56.
The outlook is mixed: high income appeals, but structural risks and analyst caution suggest volatility. Investors must weigh yield sustainability against potential capital depreciation, with entry timing critical for long-term viability.
BDX trades at $151.94, up 0.72% on the day, with a bearish technical signal despite recent earnings beats. The stock is supported by consistent revenue growth, reaching $21.84B in 2025, and a forward P/E of 26.52. Analyst consensus is mixed with a $173.40 price target, and the company maintains a solid dividend, recently paying $1.05 per share. Cash flow trends show variability, with 2025 net cash flow negative $1.00B, though 2026 projects a positive $346M.
The outlook for BDX balances strong fundamentals against near-term headwinds. Revenue growth and strategic positioning in medical technology offer upside, but investor sentiment is cautious due to bearish technicals and margin pressures. Risks include hospital spending caution and competitive dynamics. The stock presents a hold case for long-term investors, with potential catalysts from continued earnings outperformance and innovation in healthcare technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
